SCHEMBL851244

SCHEMBL851244

CCOC(=N)c1ccc(Oc2cc(Oc3ccc(C(=N)OCC)cc3)cc(C(=O)N3CCN(C(=O)CCN)CC3)c2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRSS1 P07477 7/20 0.53
PRSS2 P07478 7/20 0.53
PRSS3 P35030 7/20 0.53
ST14 Q9Y5Y6 6/20 0.53
F2 P00734 4/20 0.53
PLG P00747 4/20 0.50
ALDH1A1 P00352 3/20 0.47
PARP10 Q53GL7 2/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.45
TP53 P04637 2/20 0.44
USP2 O75604 1/20 0.42
F10 P00742 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HRH2 P25021 1/20 0.41
HRH1 P35367 1/20 0.41
TPSAB1 Q15661 1/20 0.41
TPSD1 Q9BZJ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL851879 0.88 PRSS1 (0.53) PRSS1PRSS2PRSS3ST14F2
SCHEMBL852113 0.86 ST14 (0.69) PRSS1PRSS2PRSS3ST14F2
SCHEMBL850475 0.86 PRSS1 (0.52) PRSS1PRSS2PRSS3ST14F2
SCHEMBL852072 0.84 ALDH1A1 (0.55) PRSS1PRSS2PRSS3ST14F2
SCHEMBL850652 0.80 F10 (0.58) PRSS1PRSS2PRSS3ST14F2
SCHEMBL861362 0.80 ALDH1A1 (0.49) PRSS1PRSS2PRSS3ST14F2
SCHEMBL851129 0.79 PRSS1 (0.69) PRSS1PRSS2PRSS3ST14F2
SCHEMBL850948 0.78 PRSS1 (0.67) PRSS1PRSS2PRSS3ST14F2
SCHEMBL852003 0.78 PRSS1 (0.66) PRSS1PRSS2PRSS3ST14F2
SCHEMBL851299 0.77 ST14 (0.62) PRSS1PRSS2PRSS3ST14F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140200225-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2014-07-17 US disclosed
US-8722930-B2 Protease inhibitors ORION CORPORATION (FI) 2014-05-13 US disclosed
US-20120136002-A1 PROTEASE INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-05-31 US disclosed
EP-2432556-A1 PROTEASE INHIBITORS Orion Corporation (FI) 2012-03-28 EP disclosed
WO-2010133748-A1 PROTEASE INHIBITORS ORION CORPORATION (FI) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140200225-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 PRSS1 3/4885PRSS2 23/4885PRSS3 11/4885
US-20120136002-A1 PROTEASE INHIBITORS SERPINB1, TMPRSS15, PRSS1 PRSS1 3/4885PRSS2 23/4885PRSS3 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.